Effect of prucalopride on symptoms of chronic constipation

Neurogastroenterology and Motility

Volumn 26, Issue 1, 2014, Pages 21-27

  Tack, J ^a   Stanghellini, V ^b   Dubois, D ^c   Joseph, A ^d   Vandeplassche, L ^e   Kerstens, R ^e  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d Health Economics and Outcomes Research   (Switzerland)

^e Movetis NV   (Belgium)

Author keywords

Abdominal discomfort; Bloating; Chronic constipation; PAC SYM; Painful bowel movements; Prucalopride

Indexed keywords

PLACEBO; PRUCALOPRIDE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOATING; CHRONIC CONSTIPATION; CHRONIC DISEASE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; HUMAN; INTESTINE FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PAINFUL DEFECATION; PATIENT ASSESSMENT; PATIENT ASSESSMENT OF CONSTIPATION SYMPTOMS QUESTIONNAIRE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SELF REPORT; TREATMENT DURATION;

ABDOMINAL DISCOMFORT; BLOATING; CHRONIC CONSTIPATION; PAC-SYM; PAINFUL BOWEL MOVEMENTS; PRUCALOPRIDE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BENZOFURANS; CHRONIC DISEASE; CONSTIPATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LAXATIVES; MIDDLE AGED; SEROTONIN 5-HT4 RECEPTOR AGONISTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890227444     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12217     Document Type: Article

References (22)

1. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004; 99: 750-9.
2. Stewart W, Liberman J, Sandler R et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Am J Gastroenterol 1999; 94: 3530-40.
3. Rome III diagnostic criteria for functional gastrointestinal disorders. Available at: http://www.romecriteria.org/assets/pdf/19_RomeIII_apA_885-898.pdf (accessed 11 July 2012).
4. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther 2007; 25: 599-608.
5. Herz MJ, Kahan E, Zalevski S, Aframian R, Kuznitz D, Reichman S. Constipation: a different entity for patients and doctors. Fam Pract 1996; 13: 156-9.
6. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
7. World Gastroenterology Organisation Practice Guidelines: Constipation. World Gastroenterology Organisation, 2007. Available at: http://www.worldgastroenterology.org/assets/downloads/en/pdf/guidelines/05_constipation.pdf (accessed 11 July 2012).
8. Locke GR 3rd, Pemberton JH, Phillips SF. American Gastroenterological Association Medical Position Statement: guidelines on constipation. Gastroenterology 2000; 119: 1761-6.
9. American College of Gastroenterology Chronic Constipation Task Force. An evidence-based approach to the management of chronic constipation in North America. Am J Gastroenterol 2005; 100(Suppl. 1): S1-4.
10. O'Keefe EA, Talley NJ, Zinsmeister AR, Jacobsen SJ. Bowel disorders impair functional status and quality of life in the elderly: a population-based study. J Gerontol A Biol Sci Med Sci 1995; 50: M184-9.
11. Chang L. Review article: epidemiology and quality of life in functional gastrointestinal disorders. Aliment Pharmacol Ther 2004; 20(Suppl. 7): 31-9.
12. Glia A, Lindberg G. Quality of life in patients with different types of functional constipation. Scand J Gastroenterol 1997; 32: 1083-9.
13. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008; 358: 2344-54.
14. Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009; 29: 315-28.
15. Tack J, Van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009; 58: 357-65.
16. Resolor® (prucalopride). Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001012/WC500053998.pdf (accessed 11 July 2012).
17. Tack J, Quigley E, Camilleri M, Vandeplassche L, Kerstens R. Efficacy and safety of oral prucalopride in women with chronic constipation in whom laxatives have failed: an integrated analysis. United Eur Gastroenterol J 2013; 1: 48-59.
18. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. ROME II: a multinational consensus document on functional gastrointestinal disorders. Gut 1999; 45(Suppl. II): II43-7.
19. Frank L, Kleinman L, Farup C, Taylor L, Miner P Jr. Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol 1999; 34: 870-7.
20. Dubois D, Gilet H, Viala-Danten M, Tack J. Psychometric performance and clinical meaningfulness of the Patient Assessment of Constipation-Quality of Life questionnaire in prucalopride (RESOLOR) trials for chronic constipation. Neurogastroenterol Motil 2010; 22: e54-63.
21. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd edn. New Jersey: Lawrence Erlbaum Associates, 1988.
22. U.S. Department of Health and Human Services Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Available at: http://www.ispor.org/workpaper/FDA%20PRO%20Guidance.pdf (accessed December 2009).